Close Menu

NEW YORK (GenomeWeb) – Danaher has completed its roughly $13.8 billion acquisition of Pall, a provider of filtration, separation, and purification products for life sciences and other applications.

Under terms of the merger, each outstanding share of Pall common stock was cancelled and converted into the right to receive $127.20 per share in cash.

The firms inked the deal in May. The $13.8 billion price tag includes assumed debt and is net of acquired cash.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.

Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.

Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.

In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.